Rhythm and conduction disorders as a manifestation of cardiotoxicity in cancer treatment

Cardio-oncology is a new field, uniting two fields of medicine. With the improvement of anti-cancer therapies, the survival rate of patients is increasing, which is a prerequisite for the manifestation of cardiovascular diseases, including rhythm and conduction disorders. On the other hand, the drugs themselves used to treat cancer are associated with damage to the cardiovascular system. The purpose of this publication is to provide a brief overview of rhythm and conduction disorders resulting from treatment with anticancer drugs, to present the drugs with the highest risk of cardiotoxicity and the risk factors predisposing to it.